HealthEquity, Inc
HQY
$96.51
+0.49%
HealthEquity, Inc. is a leading administrator of tax-advantaged healthcare savings accounts, primarily Health Savings Accounts (HSAs), along with consumer-directed benefits such as FSAs, HRAs, COBRA, and commuter benefits, serving employers and individual account holders across the United States. The company operates as a scaled platform in the healthcare information services industry, generating revenue through custodial fees, payment processing (card and debit), and investment advisory services on balances exceeding a threshold, which gives it a recurring, asset-gathering business model distinct from pure software or benefits administration peers. The current investor narrative centers on the durability of HSA account and asset growth, the pace of margin expansion as the company integrates prior acquisitions and scales its technology stack, and management's conservative full-year guidance, which disappointed investors even as Q2 results beat estimates. Recent headlines highlight a sharp post-earnings selloff driven by guidance rather than fundamentals, while the broader debate focuses on whether HealthEquity can sustain double-digit earnings growth and convert its growing custodial asset base into higher-margin service revenue.…
HQY
HealthEquity, Inc
$96.51
Related headlines
Investment Opinion: Should I buy HQY Today?
We rate HealthEquity a Buy, anchored by a strong buy consensus (mean 1.33) and an average target price of $119.00, implying 23.6% upside. The core thesis is that the company's dominant HSA platform, expanding margins, and robust free cash flow generation will drive earnings growth that justifies the current valuation, even as revenue growth moderates.
The supporting evidence is compelling: forward PE of 17.50x is well below the trailing PE of 34.27x, reflecting expected EPS of $5.98; gross margin expanded to 72.27% in Q1 FY2027 from 59.64% a year earlier; operating margin improved to 29.03% from 25.50%; and TTM free cash flow of $487.64 million supports aggressive share repurchases ($123.31 million in Q1 alone). The PEG ratio of 0.274 suggests the stock is undervalued relative to its growth rate.
The biggest risks are a continued deceleration in revenue growth (7.19% YoY in Q1 FY2027), potential earnings misses if the forward EPS estimate of $5.98 is not met, and a valuation multiple that could compress if growth disappoints. We would upgrade to a Strong Buy if revenue growth reaccelerates above 10% and margins continue to expand, or downgrade to Hold if revenue growth falls below 5% or if forward EPS estimates are revised downward. Relative to its history and peers, HQY appears fairly valued to slightly undervalued on a forward basis, but the trailing metrics suggest a premium.
Sign up to view all
HQY 12-Month Price Forecast
HealthEquity presents a compelling bull case driven by a low forward valuation, expanding margins, and overwhelmingly positive analyst sentiment. The forward PE of 17.50x and PEG of 0.274 suggest the stock is undervalued relative to its growth potential, while the strong buy consensus and 23.6% upside to the average target provide a favorable risk/reward. However, the recent revenue deceleration to 7.19% YoY and conservative guidance are concerns that could cap upside. We would upgrade to high confidence if revenue growth reaccelerates above 10% and EPS beats, or downgrade to neutral if growth falls below 5% or if the stock breaks below $92 support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HealthEquity, Inc's 12-month outlook, with a consensus price target around $119.00 and implied upside of +23.3% versus the current price.
Average Target
$119.00
0 analysts
Implied Upside
+23.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $142
Analyst target range
HealthEquity is covered by 15 analysts with a consensus recommendation of "strong_buy" and a recommendation mean of 1.33 (where 1.0 is a strong buy), indicating overwhelmingly bullish sentiment. The average target price is $119.00, which implies approximately 23.6% upside from the current price of $96.26, and the full target range spans from a low of $105.00 to a high of $142.00. The consensus EPS estimate for the forward year is $5.98, with a range of $5.38 to $6.42, and estimated revenue averages $1.61 billion, ranging from $1.58 billion to $1.65 billion. The bullish consensus is notable given the stock's recent 8.76% one-month decline, suggesting analysts view the post-earnings pullback as a buying opportunity rather than a fundamental deterioration. The target range is relatively wide, with the high target of $142.00 representing 47.5% upside and the low target of $105.00 representing just 9.1% upside, a spread of $37.00 or 38.5% of the average target, which signals meaningful uncertainty about the company's growth trajectory. The high target likely assumes accelerating HSA asset growth, successful margin expansion, and multiple expansion toward the higher end of the historical range, while the low target appears to price in continued revenue deceleration and a conservative guidance environment. Institutional ratings show a clear pattern of upgrades and reiterations: BMO Capital upgraded to Outperform from Market Perform on April 9, 2026, and firms including RBC Capital, Citizens, Barrington Research, Deutsche Bank, JP Morgan, and Barclays have all maintained bullish ratings (Outperform, Buy, or Overweight) through mid-2026. The absence of any Sell or Underperform ratings and the recent upgrade activity reinforce the strong conviction among analysts, though the wide target spread and the stock's recent underperformance relative to the consensus view suggest that execution risk remains the key swing factor.
Bulls vs Bears: HQY Investment Factors
The bull case rests on a strong buy consensus with 23.6% upside, a low forward PE of 17.5x, expanding margins, and robust free cash flow, while the bear case highlights decelerating revenue growth (7.19% YoY), conservative guidance, a wide analyst target spread, and a trailing PE of 34.3x that leaves little room for error. Currently, the bull evidence is stronger: analysts are overwhelmingly positive, the forward valuation is attractive, and the balance sheet is solid. However, the single most important tension is whether revenue growth can reaccelerate toward low-double-digits; if it does, the stock likely re-rates higher, but if deceleration continues, the forward earnings estimates that justify the current price may be at risk.
Bullish
- Strong Buy Consensus, 23.6% Upside: All 15 covering analysts rate HQY a strong buy (mean 1.33), with an average target of $119.00 implying 23.6% upside from $96.26. Even the lowest target of $105.00 offers 9.1% upside, suggesting a favorable risk/reward skew.
- Forward PE of 17.5x Is Attractive: The forward PE of 17.50x is less than half the trailing PE of 34.27x, reflecting expected EPS growth to $5.98. The PEG ratio of 0.274 is exceptionally low, indicating the stock is cheap relative to its earnings growth rate.
- Margin Expansion Is Accelerating: Q1 FY2027 gross margin expanded to 72.27% from 59.64% a year earlier, while operating margin rose to 29.03% from 25.50%. Net income jumped 28.8% YoY to $69.42 million, demonstrating strong operating leverage.
- Robust Free Cash Flow and Balance Sheet: TTM free cash flow is $487.64 million, comfortably funding $123.31 million in quarterly share repurchases. With a current ratio of 3.27 and debt-to-equity of 0.475, the balance sheet is healthy and not reliant on external financing.
Bearish
- Revenue Growth Decelerating Sharply: Q1 FY2027 revenue grew just 7.19% YoY to $354.64 million, down from 10.3% YoY growth in Q2 FY2026. This deceleration likely triggered the conservative guidance and the 10.6% single-day post-earnings drop.
- Conservative Guidance Disappointed: Despite beating Q2 estimates, management's full-year guidance was too conservative, signaling that investors expected more. The stock fell from $104.42 to $93.39 on August 27, 2026, and remains 10.5% below its 52-week high of $107.62.
- Wide Analyst Target Spread Signals Uncertainty: The target range spans $105.00 to $142.00, a spread of $37.00 or 38.5% of the average target. This wide dispersion indicates meaningful disagreement about the company's growth trajectory and execution risk.
- Trailing PE of 34.3x Is Not Cheap: The trailing PE of 34.27x sits in the middle of its historical range, and the price-to-free-cash-flow ratio of 71.27x suggests the stock is not a deep value play. The market is pricing in a significant earnings inflection that must be delivered.
HQY Technical Analysis
HealthEquity is in a broad recovery uptrend, with the current price of $96.26 sitting roughly 89.5% of the way through its 52-week range of $72.76 to $107.62, and a 1-year price change of +4.25% that masks a much stronger 6-month gain of +23.71%. This positioning near the upper end of the range signals that momentum buyers have been in control for most of 2026, but it also leaves the stock vulnerable to profit-taking, especially given the 30.57% max drawdown recorded over the past year. The stock is not at an extreme overbought level relative to its highs, but the proximity to resistance means the risk/reward for new longs is less favorable than it was in the spring. Recent momentum has decelerated sharply: the 1-month change is -8.76% versus a 3-month gain of +8.97%, a clear negative divergence from the longer-term uptrend, and relative strength versus SPY over the past month is -7.70 percentage points. This pullback followed the late-August earnings-related drop from $104.42 on August 26 to $93.39 on August 27, a single-day decline of roughly 10.6%, and the stock has since stabilized in the $92-$98 range. The 1-month weakness against a positive 3-month and 6-month trend suggests a temporary correction or mean-reversion event rather than a full trend reversal, but the failure to reclaim the $104-$106 area keeps the near-term bias cautious. Key technical support sits at the 52-week low of $72.76, with a more immediate support zone around $92-$93 defined by the August 27 low and recent consolidation; resistance is the 52-week high of $107.62, and a breakout above that level would confirm the resumption of the primary uptrend and likely target new highs. A breakdown below $92 would signal that the post-earnings selling pressure is intensifying and could open the door to a retest of the $85-$88 area. With a beta of just 0.225, HealthEquity is roughly 78% less volatile than the broader market, which means position sizing can be larger for the same risk budget, but it also implies the stock may lag in strong risk-on rallies and that the recent 10% single-day drop was an idiosyncratic, news-driven event rather than a market beta effect.
Beta
0.23
0.23x market volatility
Max Drawdown
-30.6%
Largest decline past year
52-Week Range
$73-$108
Price range past year
Annual Return
+3.8%
Cumulative gain past year
| Period | HQY Return | S&P 500 |
|---|---|---|
| 1m | -7.8% | -2.4% |
| 3m | +11.8% | +2.2% |
| 6m | +19.0% | +14.8% |
| 1y | +3.8% | +14.6% |
| ytd | +6.0% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HQY Fundamental Analysis
HealthEquity's revenue trajectory remains solidly positive but is showing signs of moderation: Q1 FY2027 (quarter ended April 30, 2026) revenue was $354.64 million, up 7.19% year-over-year from $330.84 million in the prior-year quarter, while the sequential trend across the last four quarters ($322.16M, $325.84M, $334.59M, $354.64M) shows consistent sequential growth. The most recent quarter's 7.19% YoY growth is slower than the 10.3% YoY growth implied by Q2 FY2026 revenue of $325.84 million versus $299.93 million a year earlier, indicating a deceleration that likely contributed to the conservative guidance reaction. Segment data shows the Financial Service, Other line at $174.33 million and Service revenue at $122.93 million, with Credit and Debit Card at $57.38 million, meaning the custodial and service-based revenue streams dominate and are the key drivers of the growth story. The investment case hinges on whether HSA asset growth and rising interest income on custodial balances can reaccelerate revenue growth toward the low-double-digit range, and the current 7.19% print suggests the company is not yet there. Profitability is robust and improving: Q1 FY2027 net income was $69.42 million with a net margin of 19.57%, up from $53.92 million and a 16.30% net margin in the prior-year quarter, while gross margin expanded to 72.27% from 59.64% a year earlier. Operating income rose to $102.95 million (29.03% operating margin) from $84.35 million (25.50% margin), and EBITDA was $105.95 million, or 29.88% of revenue, versus $124.55 million and 37.65% a year ago, with the EBITDA decline reflecting the prior-year period's unusually high margin base. The gross margin expansion is notable and suggests a favorable revenue mix shift toward higher-margin custodial and service fees, though the quarterly gross margin can be volatile due to cost-of-revenue timing. The balance sheet and cash flow profile are healthy: debt-to-equity is 0.475, the current ratio is 3.27, and TTM free cash flow is $487.64 million, which comfortably covers the company's capital needs and supports its aggressive share repurchases ($123.31 million in Q1 FY2027 alone). ROE is 10.21% and ROA is 6.65%, which are respectable for a capital-light administrator but not exceptional, and the company's cash flow coverage of debt (operating cash flow of $97.53 million in the quarter against total debt) is adequate. The main financial risk is the $15 million quarterly debt repayment schedule and the $12.59 million interest expense, which consumes a meaningful portion of operating income, but with $265.37 million in cash and strong FCF generation, HealthEquity is not dependent on external financing to fund growth.
Quarterly Revenue
$354641000.0B
2026-04
Revenue YoY Growth
+7.2%
YoY Comparison
Gross Margin
72.3%
Latest Quarter
Free Cash Flow
$487637000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HQY Overvalued?
Because HealthEquity is profitable with positive net income of $69.42 million in the most recent quarter and TTM earnings, the PE ratio is the appropriate primary valuation metric; the trailing PE is 34.27x while the forward PE is 17.50x, a dramatic 49% compression that implies the market expects earnings to roughly double over the next year. This gap is unusually wide and reflects both the low trailing EPS base of $0.029 (which appears distorted by one-time items or a different share count basis) and the consensus forward EPS estimate of $5.98, so the forward PE is the more meaningful figure for assessing valuation. The PEG ratio of 0.274 is exceptionally low, suggesting that even after the recent run-up, the stock is cheap relative to its expected earnings growth rate. Relative to the healthcare information services sector, HealthEquity's forward PE of 17.50x and PS ratio of 5.62x look reasonable rather than stretched, especially given its 69.52% gross margin and 24.55% operating margin, which are competitive for the industry. The EV/EBITDA of 16.48x and EV/Sales of 6.27x are moderate for a company with recurring revenue and a dominant HSA market position, though the PCF ratio of 16.14x and price-to-free-cash-flow ratio of 71.27x suggest the stock is not a deep value play on cash flow. The premium versus the broader market is justified by HealthEquity's entrenched position in a structurally growing HSA market, but the discount to high-growth software peers reflects its slower top-line growth and regulatory exposure. Historically, HealthEquity's PE ratio has ranged from negative territory in FY2023 to a high of 92.02x in Q4 FY2025 and 39.41x in Q3 FY2026, with the current trailing PE of 34.27x sitting in the lower-middle portion of that recent band. The PS ratio of 5.62x is well below the 19.53x-25.77x range seen across FY2026 quarters, though those figures appear to use a different revenue base or share count and are not directly comparable; the more reliable historical PS readings from the ratios data show 19.53x in Q1 FY2027 and 22.05x in Q4 FY2026, which would make the current 5.62x look like a steep discount. The PB ratio of 3.50x is in line with the 3.38x-3.91x range over the past year, indicating the market is valuing equity at a consistent multiple. Overall, the valuation appears to be in the middle-to-lower end of its own historical range, which could represent a value opportunity if earnings growth materializes as consensus expects, but the wide gap between trailing and forward PE also signals that the market is pricing in a significant earnings inflection that must be delivered to justify the current price.
PE
34.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 25x~142x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.5x
Enterprise Value Multiple
Investment Risk Disclosure
HealthEquity's financial risks are moderate but manageable. The company carries debt-to-equity of 0.475 and faces $12.59 million in quarterly interest expense, which consumes about 12.2% of operating income. While TTM free cash flow of $487.64 million comfortably covers this, the quarterly debt repayment schedule of $15 million adds a fixed obligation. Revenue growth decelerated to 7.19% YoY in Q1 FY2027 from 10.3% a year earlier, and if this trend continues, it could pressure margins and cash flow. Additionally, the company's revenue is concentrated in HSA custodial and service fees, making it sensitive to changes in healthcare spending and interest rates on custodial balances.
Market and competitive risks are significant given the stock's premium valuation and recent momentum reversal. The trailing PE of 34.27x and price-to-free-cash-flow of 71.27x leave little room for disappointment, and the 1-month decline of 8.76% versus a 3-month gain of 8.97% shows how quickly sentiment can shift. With a beta of only 0.225, HQY is less sensitive to broad market moves, but this also means it may lag in strong rallies. The recent post-earnings selloff, driven by conservative guidance rather than fundamentals, highlights the market's high expectations. Competitive threats from larger benefits administrators or fintech entrants could pressure pricing and market share.
In a worst-case scenario, a continued deceleration in revenue growth, combined with a miss on forward EPS estimates, could trigger a sharp re-rating. If the stock were to retest its 52-week low of $72.76, that would represent a 24.4% decline from the current price of $96.26. The analyst low target of $105.00 is above the current price, but in a severe downturn, the stock could fall to the $72-$75 range, implying a loss of 22-24%. A breakdown below the $92 support level could accelerate selling toward the $85-$88 area, and ultimately the 52-week low.
FAQ
The key risks include: 1) Revenue growth deceleration, with Q1 FY2027 growth at 7.19% YoY, down from 10.3% a year earlier, which could pressure the valuation if it continues. 2) Valuation compression, as the trailing PE of 34.27x and price-to-free-cash-flow of 71.27x leave little room for error. 3) Competitive threats from larger benefits administrators or fintech entrants that could erode market share and pricing power. 4) Regulatory changes to HSA tax advantages, which could reduce demand for the company's core products. These risks are ranked from most to least severe, with revenue deceleration being the most immediate concern.
Our 12-month forecast has three scenarios: a bull case with 30% probability targeting $119-$142, a base case with 50% probability targeting $105-$119, and a bear case with 20% probability targeting $72.76-$105. The base case is most likely, assuming revenue growth stabilizes around 7-8% and EPS meets the consensus of $5.98. The key assumption is that interest rates remain stable and no major regulatory changes occur. In the bull case, revenue reaccelerates above 10% and margins expand further, while the bear case assumes a revenue miss and multiple compression.
HQY appears fairly valued to slightly undervalued on a forward basis. The forward PE of 17.50x is below the trailing PE of 34.27x, reflecting expected earnings growth, and the PEG ratio of 0.274 is exceptionally low, suggesting the stock is cheap relative to its growth rate. The PS ratio of 5.62x and EV/EBITDA of 16.48x are moderate for a company with recurring revenue and a dominant market position. Compared to its own history, the current trailing PE is in the middle of its recent range, while the forward PE suggests a discount if earnings materialize. The market is pricing in an earnings inflection that must be delivered to justify the current price.
From a risk/reward perspective, HQY appears attractive for investors with a medium to long-term horizon. The stock trades at a forward PE of 17.50x, well below its trailing PE of 34.27x, and analysts have a strong buy consensus with an average target of $119.00, implying 23.6% upside. The biggest downside risk is a continued deceleration in revenue growth, which could lead to a retest of the 52-week low of $72.76, representing a 24.4% decline. However, the company's robust free cash flow of $487.64 million and expanding margins provide a cushion. It is a good buy for investors comfortable with moderate volatility and confident in the HSA growth story, but those seeking deep value may find better opportunities elsewhere.
HQY is more suitable for long-term investment due to its low beta of 0.225, recurring revenue model, and structural growth in the HSA market. The stock does not pay a dividend, so returns depend on capital appreciation, which requires patience as the company executes on its growth strategy. Short-term trading is less attractive given the recent 8.76% one-month decline and the wide analyst target spread, which indicates uncertainty. A minimum holding period of 2-3 years is recommended to allow for revenue reacceleration and margin expansion to play out, and to ride out any near-term volatility.